No profile data available.
Reviva Pharmaceuticals Holdings, Inc. (RVPH) is a healthcare company in the brain and nerve treatment drugs industry, based in Cupertino, United States, with about 14 full-time employees.
It reported revenue of $0 for fiscal year 2024, and net income of -$29.92 million. In Q3 2025 (the quarter ended September 30, 2025) revenue was $0. Its market capitalization was $6.56 million as of October 9, 2026.
Figures from company filings and market data; latest fiscal year ended December 31, 2024; market data as of October 9, 2026.
, a biopharmaceutical company, discovers, develops, and commercializes next-generation therapeutics for diseases targeting unmet medical needs in the areas of central nervous system, respiratory, inflammatory, and cardiometabolic diseases.
Reviva Pharmaceuticals reported $0 in revenue for fiscal year 2024. In Q3 2025 revenue was $0.
$6.56 million as of October 9, 2026.
Listed companies of a similar size in the same industry (brain and nerve treatment drugs) include NKGen Biotech, Inc. (NKGN), NeuroSense Therapeutics Ltd. (NRSN), Brainstorm Cell Therapeutics Inc. (BCLI), Enveric Biosciences, Inc. (ENVB).